The exosomes market size valued at USD 0.182 Billion in 2022. The Global exosomes market industry is projected to grow from USD 0.237 Billion in 2023 to USD 1.984 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 30.40% during the forecast period (2024 - 2032). Increased incidence of cancer and rising R&D activities related to exosome research are the key market drivers enhancing the market growth.
Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for exosomes is being driven by a rising focus on personalized medicine and targeted drug delivery. Exosomes, small extracellular vesicles secreted by various cell types, have garnered significant attention for their role in intercellular communication and their potential applications in diagnostics and therapeutics. As researchers continue to unravel the complex functions of exosomes, there is growing recognition of their ability to serve as natural carriers for biomolecules such as proteins, nucleic acids, and lipids. This inherent cargo-carrying capacity makes exosomes attractive vehicles for delivering therapeutic payloads to specific target cells or tissues, offering a promising avenue for precision medicine approaches.
Moreover, the rise of precision medicine has spurred the development of innovative strategies for diagnosing and treating diseases based on individual genetic, environmental, and lifestyle factors. Exosomes have emerged as promising biomarkers for various health conditions, including cancer, neurodegenerative disorders, and infectious diseases. Their presence in bodily fluids such as blood, urine, and saliva enables non-invasive and minimally invasive diagnostic tests that can provide valuable insights into disease progression, prognosis, and treatment response. The ability to detect and analyze exosomes allows for early disease detection, patient stratification, and monitoring of treatment efficacy, contributing to improved clinical outcomes and patient care. Furthermore, the growing interest in regenerative medicine and cell-based therapies has fueled the exploration of exosomes as novel therapeutic agents. Exosomes derived from stem cells or other cell types possess regenerative and immunomodulatory properties that make them attractive candidates for treating tissue injury, degenerative diseases, and immune-related disorders. By harnessing the therapeutic potential of exosomes, researchers aim to develop innovative treatments that can promote tissue repair, modulate immune responses, and enhance patient recovery.
Additionally, advancements in exosome isolation, characterization, and engineering technologies have facilitated their translation from research tools to clinical applications. Various methods, including ultracentrifugation, size-exclusion chromatography, and microfluidic-based techniques, enable efficient isolation and purification of exosomes from complex biological samples. Furthermore, advancements in analytical techniques such as mass spectrometry, flow cytometry, and nanoparticle tracking analysis allow for the comprehensive characterization of exosome cargo and surface markers, enhancing our understanding of their biological functions and therapeutic potential. Therefore, the convergence of personalized medicine, biomarker discovery, and regenerative therapies is driving rapid growth in the exosomes market. Thus driving the exosomes market revenue.
The exosomes market segmentation, based on products & services, includes kits & reagents, instruments, and services. In 2023, the kits & reagents segment will dominate the market by providing essential tools for the isolation, quantification, and analysis of exosomes. These specialized kits offer convenience, consistency, and reproducibility, facilitating research and clinical applications. With a broad range of offerings tailored to diverse experimental needs, kits & reagents drive efficiency and standardization in exosome-related studies. Further, the services are the fastest growing due to the increasing demand for expertise in exosome isolation, characterization, and analysis.
Figure 1: Exosomes Market, by Products & Services, 2023 & 2032 (USD Billion)
Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review
The Exosomes market segmentation, based on application, includes Diagnostic and Therapeutic. In 2023, the therapeutics category will dominate the market due to its potential in targeted drug delivery, regenerative medicine, and immunotherapy. Exosomes serve as natural carriers for therapeutic payloads, offering precise and efficient delivery to target cells or tissues, thus driving significant interest and investment in exosome-based therapeutic development. Further, the diagnostic is the fastest growing as it leverages their presence in bodily fluids for non-invasive disease detection, prognosis, and treatment monitoring.
The Exosomes market segmentation, based on indication, includes Cancer, Neurodegenerative Diseases, Cardiovascular Diseases, Infectious Diseases, and Others. In 2023, the cancer category will dominate the market due to the potential of exosomes as biomarkers for early cancer detection, prognostic indicators, and therapeutic delivery vehicles. Their role in intercellular communication and tumor progression provides a rich source of diagnostic and therapeutic targets, driving extensive research and development in oncology. Further, neurodegenerative diseases are the fastest growing due to the increasing prevalence of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as the growing interest in exosomes as a potential therapeutic option for these diseases.
By region, the study offers market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Exosomes market area dominates this market due to a well-developed and advanced healthcare infrastructure with rising government funding. Additionally, the region has a rising demand for precision medicine approaches, including the development of targeted therapies.
Further, the primary countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, India, Japan, Australia and South Korea.
Figure 2: EXOSOMES MARKET SHARE BY REGION 2023 (USD Billion)
Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe's exosomes market accounts for the second-largest market share due to the increasing number of chronic diseases and government initiatives. Further, the German Exosomes market held the largest market share, and the UK Exosomes market was the fastest-growing market in the European region.
The Asia-Pacific Exosomes Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to rising spending on healthcare infrastructure, rising investment in R&D activities, and government emphasis. Moreover, China’s Exosomes market held the largest market share, and the Indian Exosomes market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Exosomes market grow even more. Market players are also undertaking different strategic activities to spread their footprint, with important market developments including new product launches, contractual agreements, higher investments, mergers and acquisitions, and collaboration with other organizations. To expand and sustain in a more competitive and rising market climate, the exosome industry must offer cost-effective items.
Manufacturing to minimize operational costs is one of the key business tactics utilized by manufacturers in the exosomes industry to benefit clients and increase the market sector. In recent years, the exosome industry has offered some of the most significant advantages to healthcare. Major players in the exosomes market, including Danaher (Beckman Coulter Inc.), Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, and Thermo Fisher Scientific Inc., and others, are trying to raise market with the investment in research and development operations.
Bio-Techne Corporation is a leading provider of life science tools and diagnostics, specializing in proteins, antibodies, assays, and instruments. Founded in 1976, the company has grown through acquisitions and internal development, establishing itself as a leader in the biotechnology industry. Bio-Techne's products are utilized by researchers and clinicians worldwide for applications in areas such as cancer research, immunology, neuroscience, and cell biology. With a commitment to innovation and quality, Bio-Techne continues to expand its product portfolio and invest in cutting-edge technologies to support advancements in biomedical research and improve patient outcomes. In February 2022, Bio-Techne signed an exclusive agreement with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test designed by Bio-Techne. This liquid biopsy provides allograft health information that is best for clinical and research applications.
Fujifilm Diosynth Biotechnologies is one of the leading contract development and manufacturing organizations (CDMO) specializing in the development and production of biopharmaceuticals. Founded in 2011 through the merger of Fujifilm's Biopharmaceutical Contract Manufacturing Business and Diosynth Ltd., the company offers a comprehensive range of services spanning from cell line development and process development to cGMP manufacturing of biologics and viral vaccines. Fujifilm Diosynth Biotechnologies operates state-of-the-art facilities in the United States (Research Triangle Park, North Carolina, and College Station, Texas) and the United Kingdom (Billingham, North East England), equipped with advanced technologies and a strong quality management system. In October 2022, Fujifilm Diosynth Biotechnologies came into a strategic collaboration with RoosterBio to allow GMP-compliant manufacturing of exosome and cell therapies.
July 2022: Cells Group announced the launch of its novel product with new lyophilized exosome technology. This new product line of the company includes innovative anti-aging products that can regenerate cells and tissues in the body.
October 2022: Neural exosome treatment opportunities and a lead program, AB126, were presented by Aruna Bio, Inc. at the Exosome-based Therapeutic Development Summit in Boston. AB126 is an unmodified neural-derived exosome with the ability to cross the blood-brain barrier.
November 2021: A manufacturing partner, Lonza partner to the biotech, pharma and nutrition industries, declared the acquisition of an exosome manufacturing facility in Lexington, Massachusetts from Codiak Biosciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.182 Billion |
| Market Size 2023 | USD 0.237 Billion |
| Market Size 2032 | USD 1.984 Billion |
| Compound Annual Growth Rate (CAGR) | 30.40% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, The Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product & Services, Application, Indication and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Danaher (Beckman Coulter Inc.), Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, and Thermo Fisher Scientific Inc. |
| Key Market Opportunities | Development of exosome-based therapeutics for regenerative medicine applications. |
| Key Market Dynamics | Increasing adoption of exosome-based diagnostics and therapeutics in precision medicine. |
Frequently Asked Questions (FAQ) :
The Exosomes market size was valued at USD 0.237 Billion in 2023.
The market is foreseen to rise at a CAGR of 30.40% during the forecast period, 2024-2032.
North America held the biggest share of the market
The primary players in the market are Danaher (Beckman Coulter Inc.), Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen and Thermo Fisher Scientific Inc.
The therapeutic category dominated the market in 2023.
Cancer has the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
